SCHEDULE: FMR LLC Reports 12% Stake in VOR BIOPHARMA INC

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 12.0% of VOR BIOPHARMA INC's common stock as of July 31, 2026.

Summary

• FMR LLC, through its subsidiaries and affiliates (collectively, the "FMR Reporters"), and Abigail P. Johnson have filed an amendment to their Schedule 13G.
• The filing reports beneficial ownership of 6,509,996 shares of VOR BIOPHARMA INC common stock.
• This represents 12.0% of the class of securities outstanding as of July 31, 2026.
• FMR LLC is identified as a holding company (HC), and Abigail P. Johnson is identified as an investment company (IN).
• The filing indicates that other persons have the right to receive or direct the sale of dividends from these securities, but no single other person holds more than five percent.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new operational or financial disclosures.

Positives

• Significant institutional ownership by FMR LLC, indicating potential confidence in the company's long-term prospects.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Negatives

• The filing does not contain new operational or financial performance data, limiting insights into the company's current health.
• The nature of the investment by FMR LLC (e.g., passive vs. active) is not detailed beyond the beneficial ownership reporting.

Risks

• Potential for future changes in FMR LLC's stake, which could impact share price volatility.
• Concentration of ownership among a few entities could influence corporate governance decisions.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding VOR BIOPHARMA INC's future performance. It solely reports on beneficial ownership.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. The 12.0% ownership by FMR LLC suggests a substantial investment, but without further context on VOR BIOPHARMA INC's specific sector or recent performance, it's difficult to gauge the immediate implications beyond indicating institutional interest.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership, potentially influencing investor sentiment.
• Management: May face increased scrutiny or engagement from FMR LLC due to their substantial stake.

Next Steps

• Continued monitoring of FMR LLC's ownership stake for any further changes.
• Analysis of VOR BIOPHARMA INC's subsequent filings for operational and financial updates.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, FMR LLC, Abigail P. Johnson, VOR BIOPHARMA INC, Institutional Investor, Common Stock